Field sting reactions in patients receiving Hymenoptera venom immunotherapy: real-life experience.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS ACS Applied Bio Materials Pub Date : 2023-09-01 DOI:10.12932/AP-011221-1282

Zeynep Çelebi Sözener, Reşat Kendirlinan, Pamir Çerçi, Ömür Ayd N, Dilşad Mungan, Sevim Bavbek, Yavuz Demirel, Zeynep Mısırl Gil, Betül Ayşe Sin

{"title":"Field sting reactions in patients receiving Hymenoptera venom immunotherapy: real-life experience.","authors":"Zeynep Çelebi Sözener, Reşat Kendirlinan, Pamir Çerçi, Ömür Ayd N, Dilşad Mungan, Sevim Bavbek, Yavuz Demirel, Zeynep Mısırl Gil, Betül Ayşe Sin","doi":"10.12932/AP-011221-1282","DOIUrl":null,"url":null,"abstract":"Background: Hymenoptera stings can cause systemic allergic reactions (SARs) that are prevented by venom immunotherapy (VIT). Sting challenge tests or field stings are used to evaluate the outcome of VIT.Objective: The aim of the study was to investigate the consequences of field stings in patients during or after completion of VIT, and to identify patients at higher risk.Methods: Patients treated with VIT between 1995 and 2018 were retrospectively evaluated. Contacted patients were invited to the clinic and a questionnaire was conducted regarding the history of field stings.Results: A total of 115 patients (F/M: 45/70, mean age: 38.5 ± 12 years) treated with VIT were included; 74/115 were contacted and asked about field stings after VIT cessation. A history of 73 field stings was reported in 38 patients, 25 of whom were treated with honeybee venom and 13 with common wasp venom. Eighteen of the reactions were SARs [8 with honeybees (1 grade-I, 6 grade-II, 1 grade-III) and 10 with common wasps (1 grade-I, 5 grade-II, 4 grade-III)]. There was no association between the severity of index reactions and field stings with either the honeybee or common wasp. The median duration of VIT was longer in patients showing no reaction than in patients with an SAR. Of the 7 patients on ACE inhibitors or beta-blockers, 1 asthmatic patient developed grade-II SAR due to field stings in the first year of VIT.Conclusions: This study confirms that VIT lasting at least 3 years is effective in preventing SARs after field stings.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12932/AP-011221-1282","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 2

Abstract

Background: Hymenoptera stings can cause systemic allergic reactions (SARs) that are prevented by venom immunotherapy (VIT). Sting challenge tests or field stings are used to evaluate the outcome of VIT.

Objective: The aim of the study was to investigate the consequences of field stings in patients during or after completion of VIT, and to identify patients at higher risk.

Methods: Patients treated with VIT between 1995 and 2018 were retrospectively evaluated. Contacted patients were invited to the clinic and a questionnaire was conducted regarding the history of field stings.

Results: A total of 115 patients (F/M: 45/70, mean age: 38.5 ± 12 years) treated with VIT were included; 74/115 were contacted and asked about field stings after VIT cessation. A history of 73 field stings was reported in 38 patients, 25 of whom were treated with honeybee venom and 13 with common wasp venom. Eighteen of the reactions were SARs [8 with honeybees (1 grade-I, 6 grade-II, 1 grade-III) and 10 with common wasps (1 grade-I, 5 grade-II, 4 grade-III)]. There was no association between the severity of index reactions and field stings with either the honeybee or common wasp. The median duration of VIT was longer in patients showing no reaction than in patients with an SAR. Of the 7 patients on ACE inhibitors or beta-blockers, 1 asthmatic patient developed grade-II SAR due to field stings in the first year of VIT.

Conclusions: This study confirms that VIT lasting at least 3 years is effective in preventing SARs after field stings.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

接受膜翅目毒液免疫疗法的患者的野外蜇伤反应：现实生活经验。

背景：膜翅目昆虫蜇伤可引起全身过敏反应，而毒液免疫疗法（VIT）可预防这种反应。毒刺激发试验或现场毒刺用于评估VIT的结果。目的：本研究的目的是调查患者在完成VIT期间或之后现场毒刺的后果，并确定风险较高的患者。方法：对1995年至2018年间接受VIT治疗的患者进行回顾性评价。接触过的患者被邀请到诊所，并进行了关于野外蜇伤史的问卷调查。结果：共纳入115例接受VIT治疗的患者（F/M:45/70，平均年龄：38.5±12岁）；联系了74/115名患者，询问VIT停止后的现场刺痛情况。据报道，38名患者有73次野外蜇伤史，其中25人接受了蜂毒治疗，13人接受了普通蜂毒治疗。其中18种反应为严重急性呼吸系统综合征[8种反应为蜜蜂（1种一级，6种二级，1种三级），10种反应为普通黄蜂（1种二级、5种二级和4种三级。）]。无论是蜜蜂还是普通黄蜂，指数反应的严重程度与野外蜇伤之间都没有关联。与SAR患者相比，无反应患者的VIT中位持续时间更长。在7名服用ACE抑制剂或β受体阻滞剂的患者中，有1名哮喘患者在VIT的第一年因野外蜇伤而出现II级SAR。结论：本研究证实，持续至少3年的VIT可有效预防野外蜇伤后的SAR。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊